Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. 10 stocks we like better than Exact Sciences › Shares of Exact Sciences (NASDAQ: EXAS) climbed on ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results , with sales up 16% year on year to $811.1 million. The company’s full-year revenue guidance of $3.15 billion at ...

Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns ...

Is Exact Sciences (NASDAQ: EXAS) about to go on a sustained run? The medical diagnostics specialist has lagged the market over the trailing-12-month period, but the stock is rebounding. In the past ...

Just after market close on Monday, Exact Sciences took the wraps off its third-quarter performance. Its revenue for the period set a new record at $851 million, for a robust 20% year-over-year ...

Abbott Laboratories' strength in Medical Devices business and the recently acquired Exact Sciences should keep driving growth ...

Exact Sciences (EXAS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Exact Sciences , maker of the Cologuard colon cancer detection test, is off to a rough start so far in 2016, with the stock down 33% so far in 2016. Some hiccups in the sales ramp-up, notably that ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

Exact Sciences' claim to fame is Cologuard, an at-home stool-based test it developed for the early detection of colorectal cancer (CRC) in patients with average risk. CRC is the third-most-common ...